BIOVIE INC

BioVie Inc. seeks to tackle life‑threatening ascites in liver cirrhosis, but its declining Nasdaq share price and negative P/E ratio highlight the risks investors face in this high‑stakes biotech race.

BioVie Inc., a biotech company focused on developing therapies for liver cirrhosis complications, faces financial challenges and market volatility despite its efforts to address a significant global health concern.